www.modernatx.com
Open in
urlscan Pro
34.196.239.46
Public Scan
URL:
https://www.modernatx.com/covid19vaccine-eua/providers/about-vaccine
Submission: On October 19 via api from QA — Scanned from DE
Submission: On October 19 via api from QA — Scanned from DE
Form analysis
0 forms found in the DOMText Content
THIS WEBSITE USES COOKIES This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use. [#OOI_PERSONAL_INFORMATION#] Use necessary cookies only I Accept Show details OK Use necessary cookies only Allow selection Allow all cookies Necessary Preferences Statistics Marketing Show details Cookie declaration [#IABV2SETTINGS#] About Necessary (9) Preferences (0) Statistics (23) Marketing (36) Unclassified (7) Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies. NameProviderPurposeExpiryType_cs_ct.contentsquare.netDetermines whether the visitor has accepted the cookie consent box. This ensures that the cookie consent box will not be presented again upon re-entry. 13 monthsHTTPak_bmscwww.modernatx.comThis cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.1 dayHTTPbm_svwww.modernatx.comUsed in context with the website's BotManager. The BotManager detects, categorizes and compiles reports on potential bots trying to access the website.1 dayHTTPCookieConsentCookiebotStores the user's cookie consent state for the current domain1 yearHTTPhas_jswww.modernatx.comRegisters whether or not the user has activated JavaScript in the browser.SessionHTTPAWSELBOptimizelyUsed to distribute traffic to the website on several servers in order to optimise response times.SessionHTTPoptimizelyRumLBOptimizelyUsed to distribute traffic to the website on several servers in order to optimise response times.SessionHTTPlanguageLinkedInSaves the user's preferred language on the website.SessionHTTPCONSENTYouTubeUsed to detect if the visitor has accepted the marketing category in the cookie banner. This cookie is necessary for GDPR-compliance of the website. 5927 daysHTTP Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in. We do not use cookies of this type. Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. NameProviderPurposeExpiryTypecollectGoogleUsed to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.SessionPixel_at.hist.#AddThisUsed by the social sharing platform AddThis to store the user's usage history of the AddThis sharing widgetPersistentHTML_cs_idt.contentsquare.netRegisters statistical data on users' behaviour on the website. Used for internal analytics by the website operator. 13 monthsHTTP_cs_root-domaint.contentsquare.netRegisters how the user has reached the website to enable pay-out of referral commission fees to partners.SessionHTTP_cs_st.contentsquare.netThis cookie is used to identify the frequency of visits and how long the visitor is on the website. The cookie is also used to determine how many and which subpages the visitor visits on a website – this information can be used by the website to optimize the domain and its subpages.1 dayHTTP_cs_same_sitet.contentsquare.netRegisters data on visitors' website-behaviour. This is used for internal analysis and website optimization. SessionHTTP_gaGoogleRegisters a unique ID that is used to generate statistical data on how the visitor uses the website.2 yearsHTTP_gatGoogleUsed by Google Analytics to throttle request rate1 dayHTTP_gidGoogleRegisters a unique ID that is used to generate statistical data on how the visitor uses the website.1 dayHTTPHistory.storewww.modernatx.comContains an visitor ID - This is used to track visitors' navigation and interaction on the website for internal website-optimization. SessionHTMLoptimizely_data$pending_eventsOptimizelyThis cookie is set to make split-tests on the website, which optimizes the website's relevance towards the visitor – the cookie can also be set to improve the visitor's experience on a website.PersistentHTMLoptimizelyEndUserIdOptimizelyUsed to measure how selected users react to targeted changes to the website's content and functionality, in order to determine what variation is most efficacious in terms of converting users to customers.179 daysHTTPslideshare.experimentsLinkedInUsed by SlideShare to determine if the visitor is participating in a design experiment.PersistentHTMLpersonalization_idTwitterThis cookie is set by Twitter - The cookie allows the visitor to share content from the website onto their Twitter profile. 2 yearsHTTPvuidVimeoCollects data on the user's visits to the website, such as which pages have been read.2 yearsHTTPhttps://#_oeu#.#$event_queueOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$layer_mapOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$layer_statesOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$session_stateOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$tracker_optimizelyOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$variation_mapOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$visitor_profileOptimizelyPendingPersistentHTMLhttps://www.modernatx.com_pending_eventsOptimizelyPendingPersistentHTML Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers. NameProviderPurposeExpiryTypelocOracleGeolocation, which is used to help providers determine how users who share information with each other are geographically located (state level).13 monthsHTTPuvcOracleDetects how often the social sharing service, AddThis, encounters the same user.13 monthsHTTPxtcOracleRegisters the user's sharing of content via social media.13 monthsHTTPIDEGoogleUsed by Google DoubleClick to register and report the website user's actions after viewing or clicking one of the advertiser's ads with the purpose of measuring the efficacy of an ad and to present targeted ads to the user.1 yearHTTPpagead/landing [x2]GoogleCollects data on visitor behaviour from multiple websites, in order to present more relevant advertisement - This also allows the website to limit the number of times that they are shown the same advertisement. SessionPixeltest_cookieGoogleUsed to check if the user's browser supports cookies.1 dayHTTPtrFacebookUsed by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.SessionPixelads/ga-audiencesGoogleUsed by Google AdWords to re-engage visitors that are likely to convert to customers based on the visitor's online behaviour across websites.SessionPixel__atuvcAddThisUpdates the counter of a website's social sharing features.13 monthsHTTP__atuvsAddThisEnsures that the updated counter is displayed to the user if a page is shared with the social sharing service, AddThis.1 dayHTTP_at.cwwAddThisUsed by the social sharing platform AddThisPersistentHTML_fbpFacebookUsed by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.3 monthsHTTP_gcl_auGoogle Tag ManagerUsed by Google AdSense for experimenting with advertisement efficiency across websites using their services. 3 monthsHTTPat-lojson-cache-#v1.addthisedge.comUsed by the social sharing platform AddThisPersistentHTMLat-randAddThisUsed by the social sharing platform AddThisPersistentHTMLoptimizelyDomainTestCookieOptimizelyTracks the conversion rate between the user and the advertisement banners on the website - This serves to optimise the relevance of the advertisements on the website. 179 daysHTTPVISITOR_INFO1_LIVEYouTubeTries to estimate the users' bandwidth on pages with integrated YouTube videos.179 daysHTTPYSCYouTubeRegisters a unique ID to keep statistics of what videos from YouTube the user has seen.SessionHTTPyt.innertube::nextIdYouTubeRegisters a unique ID to keep statistics of what videos from YouTube the user has seen.PersistentHTMLyt.innertube::requestsYouTubeRegisters a unique ID to keep statistics of what videos from YouTube the user has seen.PersistentHTMLyt-remote-cast-availableYouTubeStores the user's video player preferences using embedded YouTube videoSessionHTMLyt-remote-cast-installedYouTubeStores the user's video player preferences using embedded YouTube videoSessionHTMLyt-remote-connected-devicesYouTubeStores the user's video player preferences using embedded YouTube videoPersistentHTMLyt-remote-device-idYouTubeStores the user's video player preferences using embedded YouTube videoPersistentHTMLyt-remote-fast-check-periodYouTubeStores the user's video player preferences using embedded YouTube videoSessionHTMLyt-remote-session-appYouTubeStores the user's video player preferences using embedded YouTube videoSessionHTMLyt-remote-session-nameYouTubeStores the user's video player preferences using embedded YouTube videoSessionHTMLoptimizely_data$#$event_queueOptimizelyPendingPersistentHTMLoptimizely_data$#$eventswww.modernatx.comPendingPersistentHTMLoptimizely_data$#$layer_mapOptimizelyPendingPersistentHTMLoptimizely_data$#$layer_statesOptimizelyPendingPersistentHTMLoptimizely_data$#$session_stateOptimizelyPendingPersistentHTMLoptimizely_data$#$tracker_optimizelyOptimizelyPendingPersistentHTMLoptimizely_data$#$variation_mapOptimizelyPendingPersistentHTMLoptimizely_data$#$visitor_profileOptimizelyPendingPersistentHTML Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies. NameProviderPurposeExpiryType_cs_cvars___4906csxd.contentsquare.netPendingSessionHTTP_cs_id___4906t.contentsquare.netPending13 monthsHTTP_cs_s___4906t.contentsquare.netPending1 dayHTTP_cs_cvarswww.modernatx.comPendingSessionHTTPAnon_IDGoogle Tag ManagerPending6 daysHTTPchatOpenmoderna-hcp.prod.chweb.appPendingSessionHTMLrecurringUserwww.modernatx.comPendingSessionHTML [#IABV2_LABEL_PURPOSES#] [#IABV2_LABEL_FEATURES#] [#IABV2_LABEL_PARTNERS#] [#IABV2_BODY_PURPOSES#] [#IABV2_BODY_FEATURES#] [#IABV2_BODY_PARTNERS#] Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages. You can at any time change or withdraw your consent from the Cookie Declaration on our website. Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy. Cookie declaration last updated on 09.10.21 by Cookiebot Skip to Content This site is intended for US Vaccination Providers only. * Multi-Language Resources * Report Adverse Event * EUA Fact Sheet for Vaccination Providers * FDA EUA Letter * For Vaccine Recipients > Menu * About Our Vaccine * Storage & Handling * Dosing & Administration * Clinical Trial Data * Vaccine Eligibility * CDC Prioritization * Vaccine Availability * Becoming a Vaccination Provider * FAQs * Report Adverse Event * EUA Fact Sheet for Vaccination Providers * FDA EUA Letter * For Vaccine Recipients > Home > About Our Vaccine Download EUA Fact Sheet & Full PI for Vaccination Providers Download EUA Fact Sheet for Vaccine Recipients & Caregivers Look Up Vaccine Expiration Dates For Vaccination Providers * The Moderna COVID‑19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID‑19) for use in individuals 18 years of age and older. * The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner. WHO IS MODERNA? Moderna is a biotechnology company founded in 2010 in Cambridge, Massachusetts. At Moderna, we are pioneering a class of medicines based on messenger RNA (mRNA). Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive many aspects of biology, including in human health and disease. We are currently developing mRNA-based vaccines and therapeutics for a variety of conditions, including COVID‑19. WHAT IS THE MECHANISM OF ACTION OF THE VACCINE? The nucleoside-modified mRNA in the Moderna COVID‑19 Vaccine is formulated in lipid particles, which enable delivery of the nucleoside‑modified mRNA into host cells to allow expression of the SARS‑CoV‑2 Spike antigen. The vaccine elicits an immune response to the Spike antigen, which protects against COVID‑19. WHAT DOES IT MEAN THAT THE VACCINE IS BASED ON MRNA TECHNOLOGY? A vaccine based on messenger RNA (mRNA) technology does not use inactivated virus, attenuated virus, or any other kind of virus. The Moderna COVID‑19 Vaccine uses mRNA to provide a blueprint for your cells to build your body’s defense against the virus. This allows the body to generate an antibody response, and to retain the information in memory immune cells, with the goal of attacking the virus if the vaccinated individual is exposed. WHAT IS THE MRNA VACCINE PLATFORM VIDEO VIDEO TRANSCRIPT: WHAT IS THE MRNA VACCINE PLATFORM? [DESCRIPTION] On-screen text: What is the mRNA Vaccine Platform? For Healthcare Professionals [SPEECH] Let’s take a quick look at Moderna’s mRNA platform, which forms the basis of the Moderna COVID‑19 Vaccine. But first, please be aware of the following important information about the Moderna COVID‑19 Vaccine. [DESCRIPTION AND SPEECH] On-screen text and voice: The Moderna COVID‑19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID‑19) for use in individuals 18 years of age and older. There is no FDA-approved vaccine to prevent COVID‑19. The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner. [DESCRIPTION] On-screen text: For information on the authorized use of the Moderna COVID‑19 Vaccine and mandatory requirements of the EUA, please review the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf. [DESCRIPTION] The image of a scientific journal is displayed, with the words “Moderna”,“mRNA”, and “Est.2010” on the cover. On-screen text: IMPORTANT SAFETY INFORMATION Contraindications Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine. [SPEECH] The name Moderna might be new to you, but we’ve been focused on research and development of new medicines since 2010. [DESCRIPTION] The logos of several national and international health agencies and research organizations appear: NIH, NIAID, BARDA, Institut Pasteur, Karolinska Institutet. [SPEECH] Our research, including partnerships with leading health agencies and research organizations, has focused on a new class of medicines and vaccines based on messenger RNA, or mRNA. [DESCRIPTION] On-screen text: FIGURE 1. THE CENTRAL DOGMA A visual representation of DNA appears with an arrow pointing to a strand of mRNA, which has an arrow pointing to a protein. [SPEECH] As you know from basic biology, mRNA is used by every cell in the body to make the proteins that drive many aspects of human health and disease. [DESCRIPTION] The image of a vial appears. Next to it is a large image of different viruses with an X over them. Then the image changes to a vial with an mRNA strand next to it. The image zooms into the mRNA as a ribosome appears alongside it within a cell. The image shows the ribosome-mRNA complex producing a viral antigen. [SPEECH] A vaccine based on mRNA does not include any virus, but instead a sequence of nucleoside-modified mRNA encoding viral antigens. This technology helps the body itself produce the viral antigen, against which the body mounts an immune response. [DESCRIPTION] Everything fades except for the image of the mRNA strand. [SPEECH] The mRNA is nonreplicating, and is only present in the cell transiently. It does not enter the cell nucleus or interact with DNA. [DESCRIPTION] The image fades out and is replaced with the image of an mRNA strand enclosed within a lipid particle. On-screen text: No adjuvants or preservatives Can be stored under refrigeration up to 30 days after thawing No dilution required [SPEECH] Moderna has developed lipid particles as vehicles to deliver the mRNA into cells. This lipid technology means that the Moderna COVID‑19 Vaccine does not require adjuvants or preservatives and can be stored under refrigerated conditions for up to 30 days, once it is thawed. Please check the Fact Sheet for Vaccination Providers for details on storage and handling of the Moderna COVID‑19 Vaccine. [DESCRIPTION] A representation of the SARS‑CoV‑2 virus appears next to the lipid particle. Then the virus changes and the mRNA changes at the same time. [SPEECH] All of this research into Moderna’s mRNA platform allows for an approach that can be adapted to target specific viruses, including SARS‑CoV‑2, the virus that causes COVID‑19, by placing the mRNA code for the viral target within the platform. Please note the following important safety information for the Moderna COVID‑19 Vaccine. [DESCRIPTION] On-screen text: Important Safety Information for Moderna COVID‑19 Vaccine [DESCRIPTION AND SPEECH] On-screen text and voice: AUTHORIZED USE Moderna COVID‑19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 years of age and older. Moderna COVID‑19 Vaccine is investigational and not approved by FDA. IMPORTANT SAFETY INFORMATION Contraindications Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine. Warnings and Precautions * Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID‑19 Vaccine. * Monitor Moderna COVID‑19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html) * Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID‑19 Vaccine. * Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not protect all vaccine recipients. Adverse Reactions Adverse reactions reported in a clinical trial following administration of the Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site. Severe allergic reactions, including anaphylaxis, have been reported following administration of the Moderna COVID-19 Vaccine during mass vaccination outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID‑19 Vaccine. Reporting Adverse Events and Vaccine Administration Errors The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS): * vaccine administration errors whether or not associated with an adverse event * serious adverse events (irrespective of attribution to vaccination) * cases of Multisystem Inflammatory Syndrome (MIS) in adults * cases of COVID‑19 that result in hospitalization or death Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. Reports should include the words “Moderna COVID‑19 Vaccine EUA” in the description section of the report. Report to ModernaTX, Inc. by calling 1-866-MODERNA (1-866-663-3762) or provide a copy of the VAERS form by faxing 1-866-599-1342 or emailing ModernaPV@modernatx.com. Pregnancy and Lactation Available data on Moderna COVID‑19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Moderna COVID‑19 Vaccine on the breastfed infant or on milk production/excretion. Dosing and Schedule The Moderna COVID‑19 Vaccine is administered intramuscularly as a series of two doses (0.5mL each) 1 month apart. There are no data available on the interchangeability of the Moderna COVID‑19 Vaccine with other COVID‑19 vaccines to complete the vaccination series. Individuals who have received one dose of Moderna COVID‑19 Vaccine should receive a second dose of Moderna COVID‑19 Vaccine to complete the vaccination series. For more information, see the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information at https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf. [DESCRIPTION] The Moderna logo is displayed, along with the website ModernaTX.com. [SPEECH] Visit ModernaTX.com to learn more about mRNA technology. [DESCRIPTION] Job code is displayed on screen: US-COV-2100130 04/2021 [END OF TRANSCRIPT] STORAGE & HANDLING Learn about storage & handling of vaccine AUTHORIZED USE Moderna COVID‑19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 years of age and older. Moderna COVID‑19 Vaccine is investigational and not approved by FDA. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine. WARNINGS AND PRECAUTIONS * Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID‑19 Vaccine. Monitor Moderna COVID‑19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html). * Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html). * Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting. * Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID‑19 Vaccine. * Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not protect all vaccine recipients. ADVERSE REACTIONS Adverse reactions reported in a clinical trial following administration of the Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site. The following adverse reactions have been reported following administration of the Moderna COVID‑19 Vaccine during mass vaccination outside of clinical trials: * Severe allergic reactions, including anaphylaxis * Myocarditis * Pericarditis * Syncope Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID‑19 Vaccine. REPORTING ADVERSE EVENTS AND VACCINE ADMINISTRATION ERRORS The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS): * vaccine administration errors whether or not associated with an adverse event * serious adverse events (irrespective of attribution to vaccination) * cases of Multisystem Inflammatory Syndrome (MIS) in adults * cases of COVID‑19 that result in hospitalization or death Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1‑800‑822‑7967. Reports should include the words “Moderna COVID‑19 Vaccine EUA” in the description section of the report. Report to ModernaTX, Inc. by calling 1‑866‑MODERNA (1‑866‑663‑3762) or provide a copy of the VAERS form by faxing 1‑866‑599‑1342 or emailing ModernaPV@modernatx.com. PREGNANCY AND LACTATION Available data on Moderna COVID‑19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Moderna COVID‑19 Vaccine on the breastfed infant or on milk production/excretion. DOSING AND SCHEDULE The Moderna COVID‑19 Vaccine is administered intramuscularly as a series of two doses (0.5 mL each) 1 month apart. There are no data available on the interchangeability of the Moderna COVID‑19 Vaccine with other COVID‑19 vaccines to complete the vaccination series. Individuals who have received one dose of Moderna COVID‑19 Vaccine should receive a second dose of Moderna COVID‑19 Vaccine to complete the vaccination series. A third dose of the Moderna COVID‑19 Vaccine (0.5 mL) administered at least 28 days following the second dose of this vaccine is authorized for administration to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. Please click for Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information for more information. ABOUT MODERNA www.ModernaTX.com 1‑866‑MODERNA (1‑866‑663‑3762) 24 hours, 7 days a week MedInfo@modernatx.com OR Try the Chatbot or Visit Moderna's Medical Services Hub for more information IMPORTANT SAFETY INFORMATION Read More Minimize — CONTRAINDICATIONS Do not administer the Moderna COVID‑19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID‑19 Vaccine. WARNINGS AND PRECAUTIONS * Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine. Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html). * Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html). * Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting. * Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID‑19 Vaccine. * Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not protect all vaccine recipients. ADVERSE REACTIONS Adverse reactions reported in a clinical trial following administration of the Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site. The following adverse reactions have been reported following administration of the Moderna COVID‑19 Vaccine during mass vaccination outside of clinical trials: * Severe allergic reactions, including anaphylaxis * Myocarditis * Pericarditis * Syncope Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID‑19 Vaccine. REPORTING ADVERSE EVENTS AND VACCINE ADMINISTRATION ERRORS The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS): * vaccine administration errors whether or not associated with an adverse event * serious adverse events (irrespective of attribution to vaccination) * cases of Multisystem Inflammatory Syndrome (MIS) in adults * cases of COVID‑19 that result in hospitalization or death Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1‑800‑822‑7967. Reports should include the words “Moderna COVID- 19 Vaccine EUA” in the description section of the report. Report to ModernaTX, Inc. by calling 1‑866‑MODERNA (1‑866‑663‑3762) or provide a copy of the VAERS form by faxing 1‑866‑599‑1342 or emailing ModernaPV@modernatx.com. PREGNANCY AND LACTATION Available data on Moderna COVID‑19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Moderna COVID‑19 Vaccine on the breastfed infant or on milk production/excretion. DOSING AND SCHEDULE The Moderna COVID‑19 Vaccine is administered intramuscularly as a series of two doses (0.5 mL each) 1 month apart. There are no data available on the interchangeability of the Moderna COVID‑19 Vaccine with other COVID‑19 vaccines to complete the vaccination series. Individuals who have received one dose of Moderna COVID‑19 Vaccine should receive a second dose of Moderna COVID‑19 Vaccine to complete the vaccination series. A third dose of the Moderna COVID‑19 Vaccine (0.5 mL) administered at least 28 days following the second dose of this vaccine is authorized for administration to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. Please click for Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information for more information. * © 2021 Moderna, Inc. US-COV-2100175 09/2021 * Privacy Policy * Terms of Use * Sitemap x YOU ARE ABOUT TO LEAVE THIS WEBSITE You are now leaving www.modernatx.com, a website provided by Moderna. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. The content displayed on external websites is not controlled by Moderna, and Moderna assumes no responsibility for the information or statements on such external websites. Cancel Continue x FOR VACCINATION PROVIDERS ONLY This website contains information intended for vaccination providers in the United States only and is not intended for the general public. No, I'm not a vaccination provider Yes, I'm a vaccination provider Hello! I’m Myrna, your Moderna virtual assistant. I’m here to answer your questions about the Moderna COVID-19 Vaccine, and to support adverse event and product complaint reporting. Start Chatting x